Overview

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis(NASH)

Status:
Active, not recruiting
Trial end date:
2022-11-22
Target enrollment:
Participant gender:
Summary
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Collaborator:
Amarex Clinical Research
Treatments:
HIV Antibodies
Leronlimab
PRO-140 monoclonal antibody